Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Talquetamab, First-in-Class Bispecific Monoclonal Antibody, Granted Breakthrough Therapy by the FDA for Relapsed or Refractory Multiple Myeloma

JHOP - August 2022 Vol 12, No 4 - FDA Oncology Update
NEW BREAKTHROUGH THERAPY

On June 29, 2022, the FDA granted the investigational first-in-class anti-CD3 and anti-GPRC5D bispecific humanized monoclonal antibody talquetamab (Janssen) a breakthrough therapy designation for relapsed or refractory multiple myeloma in patients who have received ≥4 previous lines of therapy, including a proteosome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. In May 2021, the FDA granted talquetamab an orphan drug designation for the treatment of multiple myeloma.

“This breakthrough therapy designation marks an important step in the continued development of talquetamab, a first-in-class bispecific antibody T-cell engager using GPRC5D,” said Sen Zhuang, MD, PhD, Vice President, Clinical Research and Development, Janssen Research and Development, in a press release. “Despite the therapies available for patients with relapsed or refractory multiple myeloma, new targets and treatments are needed because of the heterogeneity of the disease, which can impact a patient’s response to treatment.”

This approval was based on the results of the phase 1/2 MonumenTAL-1 study, a first-in-human dose-escalation clinical trial that enrolled heavily pretreated patients with relapsed or refractory multiple myeloma. Talquetamab is currently being evaluated for the treatment of relapsed or refractory multiple myeloma, as well as in combination with the investigational T-cell redirecting bispecific antibody targeting B-cell maturation antigen teclistamab, for the treatment of relapsed or refractory multiple myeloma.

Related Items
Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in FDA Oncology Update
Breyanzi Now FDA Approved for Second-Line Treatment of Large B-Cell Lymphoma
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in FDA Oncology Update
Tafinlar plus Mekinist First Tumor Agnostic Therapy Approved for Any Unresectable or Metastatic Solid Tumors with BRAF Mutation
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in FDA Oncology Update
FDA Issues New Warning for Copiktra About Increased Risks for Serious Side Effects and Mortality
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in FDA Oncology Update
Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Lymphoma, CAR T-Cell Therapy
Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Leukemia
Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Leukemia, Pediatric Cancer
Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Breast Cancer
Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, CAR T-Cell Therapy, Lymphoma
Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Prostate Cancer
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.